Changeflow GovPing Pharma & Drug Safety Shionogi Monocyclic GLP-1 Receptor Agonist Pate...
Routine Notice Added Final

Shionogi Monocyclic GLP-1 Receptor Agonist Patent Application

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

Shionogi & Co., Ltd. filed USPTO Patent Application US20260098031A1 for a monocyclic compound demonstrating GLP-1 receptor agonist activity, along with pharmaceutically acceptable salts. The compound, classified under CPC codes C07D 405/14 and A61K 31/4439, is intended for pharmaceutical use. The application, published April 9, 2026, claims priority to the September 2023 filing date.

What changed

Shionogi & Co., Ltd. filed USPTO Application US20260098031A1, a patent application for a monocyclic compound represented by formula (I) having GLP-1 receptor agonist activity, along with pharmaceutical salts. The compound features a 5-membered heterocyclic core with varying ring nitrogens, pendant alkyl linkers, and phenyl substituents bearing halogen, cyano, alkyl, haloalkyl, alkyloxy, or haloalkyloxy groups. Claimed uses include pharmaceutical applications for metabolic disorders.

Pharmaceutical companies and researchers in the GLP-1 agonist space should monitor this application's prosecution. Competitors developing similar GLP-1 receptor modulators may need to assess design-around strategies or explore cross-licensing. The compound's monocyclic (non-peptide) structure contrasts with existing peptide-based GLP-1 therapies, potentially offering IP coverage in a distinct chemical space.

What to do next

  1. Monitor patent prosecution for granted claims
  2. Assess licensing opportunities for GLP-1 receptor agonist compound
  3. Review compound structure for potential design-around options

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

MONOCYCLIC COMPOUND HAVING GLP-1 RECEPTOR AGONIST ACTIVITY

Application US20260098031A1 Kind: A1 Apr 09, 2026

Assignee

Shionogi & Co., Ltd.

Inventors

Yuji NISHIURA

Abstract

The present invention relates to a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof. A compound represented by formula (I): whereinA1 is C(R5) or N,A2 is C(R6) or N,A3 is C(R7) or N,R5, R6, and R7 are each independently a hydrogen atom or the like,R2 is substituted or unsubstituted alkyl or the like,-L- is a group represented by: whereinR1 is a hydrogen atom or the like,R8 is a hydrogen atom or the like,R10s are each independently cyano or the like,m is an integer of 1 to 3, andR3 is phenyl optionally substituted with substituent group F, or the like,the substituent group F: halogen, cyano, alkyl, haloalkyl, alkyloxy, and haloalkyloxy.

CPC Classifications

C07D 405/14 A61K 31/4439

Filing Date

2023-09-21

Application No.

19112482

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260098031A1
Docket
19112482

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Investors
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Drug compound licensing Pharmaceutical research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Public Health Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.